-+ 0.00%
-+ 0.00%
-+ 0.00%

Formycon, MS Pharma Enter Licensing Deal for Keytruda Biosimilar in MENA

MT Newswires·12/04/2025 01:54:46
Listen to the news
01:54 AM EST, 12/04/2025 (MT Newswires) -- Formycon (FYB.F) signed a licensing and supply deal with MS Pharma to commercialize its Keytruda biosimilar candidate FYB206 across the Middle East and North Africa. The agreement, which includes an option for future technology transfer, marks the beginning of commercial partnering activities for FYB206, according to a Thursday release. The German biosimilars developer plans to pursue additional regional licensing deals in due course. Formycon will receive an upfront payment and is eligible for further milestone-based payments tied to development and regulatory progress in the high single-digit million-euro range. It will also receive a significant share of gross profits generated in the region.